Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 11/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506008 | 0.84 | PTGS2 (0.58) | PTGS2ESR1CYP19A1ESR2CYP3A4 | |
| SCHEMBL17506000 | 0.82 | CYP19A1 (0.78) | ESR1CYP19A1ESR2CYP3A4CYP1A2 | |
| SCHEMBL9100272 | 0.81 | PTGS2 (0.61) | PTGS2ESR1CYP19A1ESR2ESRRB | |
| SCHEMBL19182067 | 0.80 | CYP19A1 (0.65) | ESR1CYP19A1ESR2CYP3A4ESRRB | |
| SCHEMBL17523634 | 0.80 | CYP19A1 (0.65) | ESR1CYP19A1ESR2CYP3A4ESRRB | |
| SCHEMBL8615209 | 0.79 | ESR1 (0.81) | PTGS2ESR1CYP19A1ESR2 | |
| SCHEMBL7712232 | 0.79 | PTGS2 (0.44) | PTGS2ESR1CYP19A1ESR2CYP3A4 | |
| SCHEMBL11043479 | 0.77 | PTGS2 (0.42) | PTGS2ESR1CYP19A1ESR2CYP3A4 | |
| SCHEMBL9860588 | 0.77 | PTGS2 (0.68) | PTGS2ESR1ESR2ESRRB | |
| SCHEMBL28108412 | 0.76 | PTGS2 (1.00) | PTGS2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | THE PENN STATE RESEARCH FOUNDATION | 2017-08-03 | — | — | US | disclosed |
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | THE PENN STATE RESEARCH FOUNDATION | 2017-08-03 | — | — | US | disclosed |
| WO-2016022325-A1 | NOVEL TRIARYLETHYLENE COMPOUNDS AND METHODS USING SAME | THE PENN STATE RESEARCH FOUNDATION (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | CYP46A1, GSTA2, GSTA1 | PTGS2 1024/4885ESR1 1247/4885CYP19A1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.